In the majority of patients with chronic myeloid leukemia (CML) responding to treatment, tyrosine kinase inhibitor (TKI) therapy has to be continued indefinitely, as long as patients are receiving clinical benefit. Adherence to TKI therapy is critical to achieving optimal responses, and the high-cost of TKIs can limit their long-term use and could potentially be a barrier to adherence to therapy.

Join us for this dynamic, case-based, live webinar in collaboration with Clinical Care Options to hear from an expert panel on current recommendations and emerging strategies for treating patients with CLL.

The NCCN 2025 Lung Cancer Congress is designed to provide the interprofessional oncology care team with practical guidance on the latest updates to the NCCN Guidelines, novel and emerging therapies, recent clinical research, and strategies to align new developments with current standards of care.

This activity will help you navigate the unique complexities of managing Richter transformation, while keeping you up to date on the latest advances and emerging therapies. You will gain practical insights to identify the right patients for novel treatments, integrate new approaches into care, and recognize when referral to clinical trials can offer the best outcomes.

Smoking cessation at any time after a cancer diagnosis is associated with improved cancer outcomes, enhanced quality of life, and reduced disease among cancer survivors.

Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma with a variable course for which no standard treatment currently exists. This webinar can help you understand how to individualize and manage therapy for each patient.

In order to select optimal therapy, the decision-making process for management of metastatic breast cancer should involve careful consideration of the available evidence and available clinical trials and a detailed discussion with patients about the benefits and risks associated with all possible treatment strategies.

High-risk neuroblastoma has historically been and continues to be an immensely difficult disease to treat in the pediatric population. It is important to identify its pathophysiology and molecular pathology to understand the role of immunotherapy, the barriers encountered with immunotherapy, and the potential for promising breakthroughs in high-risk neuroblastoma.